Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | CCR3 | P51677 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760979 | 0.89 | EPHX2 (0.63) | EPHX2CYP2C9CYP2J2OPRK1SLC6A4 | |
| SCHEMBL22278187 | 0.86 | EPHX2 (0.57) | EPHX2CYP2C9CYP2J2OPRK1SLC6A4 | |
| SCHEMBL22173976 | 0.85 | EPHX2 (0.56) | EPHX2CYP2C9CYP2J2OPRK1SLC6A4 | |
| SCHEMBL2636719 | 0.85 | EPHX2 (0.56) | EPHX2CYP2C9CYP2J2OPRK1SLC6A4 | |
| SCHEMBL19610260 | 0.84 | CHRM3 (0.53) | EPHX2OPRK1KCNH2 | |
| SCHEMBL3292130 | 0.84 | OPRK1 (0.49) | EPHX2CYP2C9CYP2J2OPRK1HRH1 | |
| SCHEMBL23365152 | 0.84 | EPHX2 (0.50) | EPHX2SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL10964732 | 0.84 | EPHX2 (0.55) | EPHX2CYP2C9CYP2J2OPRK1SLC6A4 | |
| SCHEMBL2636720 | 0.84 | EPHX2 (0.55) | EPHX2CYP2C9CYP2J2OPRK1SLC6A4 | |
| SCHEMBL10608458 | 0.83 | EPHX2 (0.57) | EPHX2CYP2C9CYP2J2OPRK1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101448844-B | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists | HOFFMANN LA ROCHE | 2012-07-25 | — | — | CN | claimed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | claimed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | claimed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | claimed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | claimed |
| CN-101448844-B | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists | HOFFMANN LA ROCHE | 2012-07-25 | — | — | CN | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | EPHX2 1201/4885CYP2C9 2221/4885CYP2J2 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.